# Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

Source: https://onco.cc/trials/nct05563220/  
OnCo record `nct05563220` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Elacestrant, Alpelisib, Everolimus, Ribociclib, Palbociclib and Capivasertib in advanced solid tumours, run by Stemline Therapeutics, Inc., active and no longer recruiting.

## Summary

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT05563220 by Stemline Therapeutics, Inc., with 435 participants enrolled, started 2023-01-24 and due to reach its primary completion in 2026-12-27. Interventions recorded: Elacestrant, Alpelisib, Everolimus, Ribociclib, Palbociclib and Capivasertib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05563220
- Phase: 1/2
- Setting: A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
- Sponsor: Stemline Therapeutics, Inc.
- Enrolled: 435

## Sources

- ClinicalTrials.gov NCT05563220: https://clinicaltrials.gov/study/NCT05563220

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Alpelisib](https://onco.cc/drugs/alpelisib/), [Capivasertib](https://onco.cc/drugs/capivasertib/), [Elacestrant](https://onco.cc/drugs/elacestrant/), [Everolimus](https://onco.cc/drugs/everolimus/), [Palbociclib](https://onco.cc/drugs/palbociclib/), [Ribociclib](https://onco.cc/drugs/ribociclib/)
- companies: [Menarini / Stemline](https://onco.cc/companies/menarini/)

---
JSON: https://onco.cc/api/v1/entities/nct05563220.json